No, cefepime does not cover MRSA. Cefepime is a fourth-generation cephalosporin with strong gram-negative coverage and activity against many gram-positive bacteria, including methicillin-susceptible Staphylococcus aureus (MSSA), but it is reliably ineffective against methicillin-resistant strains. If MRSA is suspected or confirmed, a separate antibiotic with specific MRSA activity is needed.
Why Cefepime Fails Against MRSA
Cefepime works like other beta-lactam antibiotics: it binds to enzymes called penicillin-binding proteins (PBPs) that bacteria need to build their cell walls. Without functional cell walls, the bacteria break apart and die. This mechanism works well against a wide range of organisms, but MRSA carries a genetic advantage that renders it essentially invisible to cefepime.
MRSA produces a modified enzyme called PBP2a, which has a physically closed active site that intact beta-lactam antibiotics struggle to access. Even when cefepime does reach PBP2a, the binding is extremely slow and weak. The dissociation constants for beta-lactams against PBP2a range from roughly 600 to 1,600 micromolar, meaning the drug doesn’t stick around long enough to do damage. In practical terms, cefepime’s minimum inhibitory concentration (the lowest dose needed to stop bacterial growth) against MRSA ranges from 16 to over 128 mg/L. Compare that to its MIC against MSSA, which sits between 0.5 and 16 mg/L. At the concentrations achievable in human blood, cefepime simply cannot overcome MRSA’s defenses.
What Cefepime Does Cover
Cefepime earns its place in treatment because of its unusually broad spectrum, particularly against gram-negative pathogens. It is more stable against bacterial enzymes that break down antibiotics (beta-lactamases) than older cephalosporins, giving it reliable activity against organisms like Pseudomonas aeruginosa, E. coli, Klebsiella, Enterobacter, and Proteus species. On the gram-positive side, it covers Streptococcus pneumoniae, Strep pyogenes, viridans streptococci, and MSSA. It also has some activity against Bacteroides fragilis, an anaerobic bacterium commonly involved in abdominal infections.
This combination of Pseudomonas coverage and gram-positive activity makes cefepime a common choice for serious hospital-acquired infections, febrile neutropenia, and complicated urinary tract infections. But whenever MRSA is on the differential, cefepime alone leaves a dangerous gap.
How Clinicians Handle MRSA When Using Cefepime
In practice, cefepime is frequently paired with vancomycin when both gram-negative organisms and MRSA are possible culprits. This combination is standard in empiric therapy for hospital-acquired pneumonia and ventilator-associated pneumonia, where MRSA accounts for roughly 10% of bacterial isolates. Cefepime handles the gram-negative side while vancomycin targets MRSA and other resistant gram-positive organisms.
Research published in Open Forum Infectious Diseases suggests this pairing may even offer a modest synergistic benefit. In patients with MRSA bloodstream infections treated with vancomycin, the addition of cefepime during the first 72 hours appeared to provide some complementary effect. The study noted that in situations where both drugs are already warranted for empiric coverage, cefepime can serve double duty: covering gram-negative organisms while acting as the beta-lactam component of a synergistic regimen alongside vancomycin. Once culture results come back confirming MRSA, the cefepime is typically switched to a more targeted agent unless ongoing gram-negative coverage is still needed.
The One Cephalosporin That Does Cover MRSA
Nearly all cephalosporins share cefepime’s weakness against MRSA, with one important exception. Ceftaroline, a fifth-generation cephalosporin (brand name Teflaro), was specifically designed to bind PBP2a effectively. In lab testing, ceftaroline proved at least 8-fold more potent than cefepime against MRSA strains. Its activity extends even to strains with reduced susceptibility to vancomycin, including vancomycin-intermediate and vancomycin-resistant S. aureus.
Ceftobiprole, another fifth-generation cephalosporin, also demonstrates MRSA activity and is available in some countries outside the United States. These fifth-generation agents represent a fundamentally different approach to the PBP2a problem, with molecular structures designed to access the enzyme’s otherwise closed active site. For now, they remain the only cephalosporins with clinically meaningful MRSA coverage.
Cefepime Side Effects Worth Knowing
One risk that sets cefepime apart from many antibiotics is neurotoxicity. Up to 15% of ICU patients receiving cefepime may develop neurological side effects, which typically appear around four days after starting the drug. Symptoms usually begin with confusion and excessive sleepiness, and can progress to involuntary muscle jerking, seizures, and in severe cases, coma. Reduced kidney function is the single biggest risk factor, since cefepime is cleared through the kidneys. When kidney function declines, the drug accumulates to toxic levels in the bloodstream and crosses into the brain more readily.
The good news is that these symptoms are reversible once the drug is stopped. Patients with known kidney problems are often started on a different antibiotic entirely, or have their cefepime dose carefully adjusted with close monitoring of kidney function throughout treatment.